Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 361836, 7 pages
http://dx.doi.org/10.1155/2010/361836
Review Article

Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises

1Division of Hematology and Oncology, Department of Medicine, The George Washington University Medical Center, 2150 Pennsylvania Avenue Northwest, Washington, DC 20037, USA
2Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
3Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Received 31 October 2009; Accepted 30 December 2009

Academic Editor: Arkadiusz Dudek

Copyright © 2010 Jeanny B. Aragon-Ching et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [19 citations]

The following is the list of published articles that have cited the current article.

  • David E. Adelberg, and William L. Dahut, “Antiangiogenic agents in the treatment of prostate cancer,” Drug Discovery Today: Therapeutic Strategies, vol. 7, no. 1-2, pp. 9–15, 2010. View at Publisher · View at Google Scholar
  • Niall M Corcoran, and Martin E Gleave, “Targeted therapy in prostate cancer,” Histopathology, vol. 60, no. 1, pp. 216–231, 2011. View at Publisher · View at Google Scholar
  • Virginie Firlej, Jacques R. R. Mathieu, Cristele Gilbert, Loic Lemonnier, Jessica Nakhle, Catherine Gallou-Kabani, Basma Guarmit, Aurelie Morin, Natalia Prevarskaya, Nicolas Barry Delongchamps, and Florence Cabon, “Thrombospondin-1 Triggers Cell Migration and Development of Advanced Prostate Tumors,” Cancer Research, vol. 71, no. 24, pp. 7649–7658, 2011. View at Publisher · View at Google Scholar
  • G. Bousquet, J. Alexandre, C. Le Tourneau, F. Goldwasser, S. Faivre, H. de Mont-Serrat, R. Kaiser, J. L. Misset, and E. Raymond, “Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients,” British Journal Of Cancer, vol. 105, no. 11, pp. 1640–1645, 2011. View at Publisher · View at Google Scholar
  • Alexander C Small, and William K Oh, “Bevacizumab treatment of prostate cancer,” Expert Opinion on Biological Therapy, vol. 12, no. 9, pp. 1241–1249, 2012. View at Publisher · View at Google Scholar
  • Olivier Guérin, Marie-Christine Etienne-Grimaldi, Martino Monteverde, Anne Sudaka, Marie-Christine Brunstein, Patricia Formento, Laura Lattanzio, Monica Maffi, Federica Tonissi, Cécile Ortholan, Gilles Pagès, Jean-Louis Fischel, Cristiana Lo Nigro, Marco Merlano, and Gérard Milano, “Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines,” Urologic Oncology: Seminars and Original Investigations, 2012. View at Publisher · View at Google Scholar
  • Y. Hu, H. Sun, J. T. O'Flaherty, and I. J. Edwards, “15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells,” Carcinogenesis, vol. 34, no. 1, pp. 176–182, 2012. View at Publisher · View at Google Scholar
  • Gabriel Birrane, Huchun Li, Suping Yang, Souvenir D. Tachado, and Seyha Seng, “Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: Nuclear HO-1 promotes vascular endothelial growth factor secretion,” International Journal Of Oncology, vol. 42, no. 6, pp. 1919–1928, 2013. View at Publisher · View at Google Scholar
  • Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, and Timothy M. Lestingi, “Lenalidomide Monotherapy in Chemotherapy-Naïve Castration-Resistant Prostate Cancer: Final Results of a Phase II Study,” Clinical Genitourinary Cancer, 2013. View at Publisher · View at Google Scholar
  • Jose Maria Martinez-Jabaloyas, Jose Antonio March-Villalba, and Maria Mercedes Navarro-Garcia, “Anti-angiogenic therapies in prostate cancer,” Expert Opinion on Biological Therapy, vol. 13, no. 1, pp. 1–5, 2013. View at Publisher · View at Google Scholar
  • Hideki Sakai, and Yasuyoshi Miyata, “Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects,” International Journal Of Molecular Sciences, vol. 14, no. 6, pp. 12249–12272, 2013. View at Publisher · View at Google Scholar
  • Tatiana M. Tilli, Akeila Bellahcene, Vincent Castronovo, and Etel R. P. Gimba, “Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines,” Bmc Cancer, vol. 14, 2014. View at Publisher · View at Google Scholar
  • Alice Dragomir, Daniela Dinea, Marie Vanhuyse, Fabio L. Cury, and Armen G. Aprikian, “Drug costs in the management of metastatic castration-resistant prostate cancer in Canada,” Bmc Health Services Research, vol. 14, 2014. View at Publisher · View at Google Scholar
  • Fatima H. Karzai, Andrea B. Apolo, Liang Cao, Ravi A. Madan, David E. Adelberg, Howard Parnes, David G. McLeod, Nancy Harold, Cody Peer, Yunkai Yu, Yusuke Tomita, Min-Jung Lee, Sunmin Lee, Jane B. Trepel, James L. Gulley, William D. Figg, and William L. Dahut, “A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer,” BJU International, 2015. View at Publisher · View at Google Scholar
  • Francesco Boccardo, “The MAINSAIL trial: an expected failure,” The Lancet Oncology, 2015. View at Publisher · View at Google Scholar
  • Nikolaos Grivas, Anna Goussia, Dimitrios Stefanou, and Dimitrios Giannakis, “Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer.,” Central European journal of urology, vol. 69, no. 1, pp. 63–71, 2016. View at Publisher · View at Google Scholar
  • Lu Gao, Kexin Chen, Qi Gao, Xiaodan Wang, Jian Sun, and Yong-Guang Yang, “CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.,” Oncotarget, vol. 8, no. 14, pp. 22406–22413, 2017. View at Publisher · View at Google Scholar
  • Sabrin Mishel, Boris Shneyer, Lina Korsensky, Orit Goldshmidt-Tran, Tom Haber, Marcelle Machluf, and Dina Ron, “Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth.,” Scientific reports, vol. 7, no. 1, pp. 15060, 2017. View at Publisher · View at Google Scholar
  • Ali H. Zahalka, Anna Arnal-Estapé, Maria Maryanovich, Fumio Nakahara, Cristian D. Cruz, Lydia W. S. Finley, and Paul S. Frenette, “Adrenergic nerves activate an angio-metabolic switch in prostate cancer,” Science, vol. 358, no. 6361, pp. 321–326, 2017. View at Publisher · View at Google Scholar